Lb Pharmaceuticals (LBRX) Interest & Investment Income (2024 - 2026)

Lb Pharmaceuticals' Interest & Investment Income history runs 3 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 1107.63% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $6.6 million (changed N/A YoY), while the FY2025 annual figure was $3.9 million, up 127.77% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.8 million, up from $2.8 million in the prior quarter.
• The five-year high for Interest & Investment Income was $2.8 million in Q1 2026, with the low at $236000.0 in Q1 2025.
• The 3-year median for Interest & Investment Income is $545500.0 (2024), against an average of $1.2 million.
• The sharpest annual moves came in 2025 and 2026: Interest & Investment Income surged 84.11% in 2025, then jumped 1107.63% in 2026.
• Lb Pharmaceuticals' Interest & Investment Income stood at $298000.0 in 2024, then jumped by 839.6% to $2.8 million in 2025, then grew by 1.79% to $2.8 million in 2026.
• Business Quant data shows LBRX's Interest & Investment Income at $2.8 million in Q1 2026, $2.8 million in Q4 2025, and $707000.0 in Q3 2025.